{"entity":{"id":"acns0332","kind":"trial","name":"COG ACNS0332","aka":["ACNS0332"],"tldr":"ACNS0332 found that giving carboplatin alongside radiotherapy improved survival for children with the most aggressive group 3 medulloblastomas, while isotretinoin, tested in the same trial, did nothing and was dropped.","summary":"ACNS0332 randomised children and young adults with high-risk medulloblastoma (metastatic, incompletely resected or with anaplasia) to 36 Gy craniospinal radiotherapy plus weekly vincristine with or without daily carboplatin as a radiosensitiser, followed by maintenance chemotherapy with or without isotretinoin. The isotretinoin randomisation closed early for futility.\n\nCarboplatin during radiotherapy did not improve event-free survival in the whole cohort, but in the molecularly defined group 3 subgroup it improved event-free and overall survival, a finding that came from the trial's tumour profiling. The result made carboplatin radiosensitisation a standard for group 3 high-risk disease and was one of the first paediatric brain tumour trials to show benefit in a molecular subgroup.","status":"mixed","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT00392327","url":"https://clinicaltrials.gov/study/NCT00392327"}],"tags":["subtype-trials"],"related":[],"cancers":["medulloblastoma-group-3-4","medulloblastoma"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["carboplatin","vincristine","cisplatin","cyclophosphamide","isotretinoin"],"companies":["childrens-oncology-group"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["sarah-leary"],"bottlenecks":[],"keyPapers":["paper-acns0332-leary-jama-oncol-2021"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00392327","phase":"3","setting":"Newly diagnosed high-risk medulloblastoma in children aged 3 to 21: craniospinal radiotherapy with weekly vincristine, with or without daily carboplatin, and with or without isotretinoin maintenance","sponsor":"Children's Oncology Group","result":"Carboplatin radiosensitisation improved event-free and overall survival in group 3 high-risk medulloblastoma; isotretinoin maintenance was stopped for futility.","started":"2007-05-23","startedType":"actual","yearReported":2021,"enrolled":379,"enrolledBasis":"registry","outcomes":[{"endpoint":"Event-free survival at 5 years","primary":true,"unit":"%","arms":[{"name":"Carboplatin with craniospinal radiotherapy","value":66.4},{"name":"No carboplatin","value":59.2}],"p":"0.11","source":"https://doi.org/10.1001/jamaoncol.2021.2224"},{"endpoint":"Event-free survival at 5 years, group 3 medulloblastoma","unit":"%","arms":[{"name":"Carboplatin with craniospinal radiotherapy","value":73.2},{"name":"No carboplatin","value":53.7}],"p":"0.047","source":"https://doi.org/10.1001/jamaoncol.2021.2224"},{"endpoint":"Overall survival at 5 years, all evaluable participants","unit":"%","arms":[{"name":"All evaluable participants","n":261,"value":73.4,"note":"Isotretinoin randomisation closed early for futility"}],"source":"https://doi.org/10.1001/jamaoncol.2021.2224"}]},"route":"/trials/acns0332/","neighbours":{"cancer":[{"id":"medulloblastoma-group-3-4","kind":"cancer","name":"Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)","route":"/cancers/medulloblastoma-group-3-4/"},{"id":"medulloblastoma","kind":"cancer","name":"Medulloblastoma","route":"/cancers/medulloblastoma/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"isotretinoin","kind":"drug","name":"Isotretinoin","route":"/drugs/isotretinoin/"},{"id":"vincristine","kind":"drug","name":"Vincristine","route":"/drugs/vincristine/"}],"company":[{"id":"childrens-oncology-group","kind":"company","name":"Children's Oncology Group (COG)","route":"/companies/childrens-oncology-group/"}],"person":[{"id":"sarah-leary","kind":"person","name":"Sarah E. S. Leary","route":"/people/sarah-leary/"}],"paper":[{"id":"paper-acns0332-leary-jama-oncol-2021","kind":"paper","name":"ACNS0332: carboplatin during radiotherapy and isotretinoin maintenance in high-risk medulloblastoma","route":"/key-papers/paper-acns0332-leary-jama-oncol-2021/"}]}}